The management of psychodermatologic disease often involves the use of psychotropics by dermatologists. A general approach to the psychopharmacologic management of psychodermatological disease may be of assistance to the dermatologist.
Objective:
We review and provide a current psychopharmacologically based approach to management of common psychopathologies associated with psychodermatologic disorders, common side effects, and potential drug interactions that may occur with selected psychotropics.
Methods:
Using relevant MeSH terms, we performed a review of the literature from 1980 to 2006.
Results and Conclusions:
Effective psychopharmacologic management of psychodermatologic disease involves identifying and basing treatment on the associated psychopathology; familiarity with a variety of psychotropic agents, including antidepressants, anxiolytics, and antipsychotics; and the involvement of a psychiatrist when possible.
Get full access to this article
View all access options for this article.
References
1.
GuptaMAGuptaAKEllisCNKoblenzerCS. Psychiatric evaluation of the dermatology patient. Dermatol Clin2005;4:591–9.
2.
GuptaMAGuptaAK. Psychodermatology: an update. J Am Acad Dermatol1996;34:1030–46.
3.
KooJ. Psychodermatology: a practical manual for clinicians. Curr Prob Dermatol1995;7:203–25.
4.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders-revised. 4th ed.Washington (DC): American Psychiatric Association; 2000.
5.
FriedRGGuptaMAGuptaAK. Depression and skin disease. Dermatol Clin2005;23:657–64.
6.
CotterillJA. Dermatologic non-disease: a common and potentially fatal disturbance of cutaneous body image. Br J Dermatol1981;104:611–9.
7.
MannJ. The medical management of depression. N Engl J Med2005;353:1819–34.
8.
MontgomerySAHenryJMcDonaldG. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol1994;9:47–53.
9.
StahlSM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry2000;48:894–901.
10.
KroenkeKWestSLSwindleR. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. JAMA2001;286:2947–55.
11.
LeeCSKooJ. Psychopharmacologic therapies in dermatology: an update. Dermatol Clin2005;23:735–44.
12.
ThaseMERushAJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry1997;58Suppl 13:23–9.
13.
BalonR. SSRI-associated sexual dysfunction. Am J Psychiatry2006;163:1504–9.
14.
FavaM. Weight gain and antidepressants. J Clin Psychiatry2000;61Suppl 11:37–41.
15.
ZajeckaJTracyKAMitchellS. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry1997;58:291–7.
LaneRM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol1996;11Suppl 5:31–61.
18.
RosenbaumJFTollefsonGD. Fluoxetine. In: SchatzbergAFNemeroffCB, editors. Textbook of psychopharmacology. Washington (DC): American Psychiatric Publishing; 2004. p. 237–46.
19.
CreweHKLennardMSTuckerGT. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol1992;34:262–5.
20.
GreenblattDJvon MoltkeLLHarmatzJSShaderRI. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry1998;59Suppl 15:19–27.
21.
FairbanksJMGormanJM. Fluvoxamine. In: SchatzbergAFNemeroffCB, editors. Textbook of psychopharmacology. Washington (DC): American Psychiatric Publishing; 2004. p. 283–90.
22.
SchmiderJGreenblattDJvon MoltkeLL. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol1997;44:495–8.
23.
XuZHXieHGZhouHH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol1996;42:518–21.
24.
MacQueenGBornLSteinerM. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev2001;7:1–24.
25.
von MoltkeLLGreenblattDJGrassiJM. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry1999;46:839–49.
26.
BrosenKNaranjoCA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol2001;11:275–83.
27.
BallSEAhernDScatinaJKaoJ. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol1997;43:619–26.
28.
NieuwstratenCEDolovichLR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother2001;35:1608–13.
29.
LaurencicGMaloneDAJr. Side effects of antidepressants: an overview. Cleve Clin J Med2006;73:351–3.
30.
HudziakJJRettewDC. Bupropion. In: SchatzbergAFNemeroffCB, editors. Textbook of psychopharmacology. Washington (DC): American Psychiatric Publishing; 2004. p. 327–39.
31.
GreeneSLReedCESchroeterAL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol1985;12:669–75.
32.
TennysonHLevineN. Neurotropic and psychotropic drugs in dermatology. Dermatol Clin2001;19:179–97, x.
33.
NaviDKooJ. Safety update on commonly used psychotropic medications in dermatology. J Drugs Dermatol2006;5:109–15.
34.
KooJYMLeeCS. Psychotropic agents. In: WolvertonSE, editor. Comprehensive dermatologic drug therapy, 1st ed. Philadelphia: WB Saunders; 2001. p. 402–25.
35.
KoenigTWGarnis-JonesSRencicATauskFA. Psychological aspects of skin diseases. In: FreedbergIMEisenAZWolffK, editors. Fitzpatrick's dermatology, 6th ed. New York: McGraw-Hill Professional; 2003. p. 389–99.
36.
WittchenHU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety2002;16:162–71.
37.
GuptaMAGuptaAK. The use of psychotropic drugs in dermatology. Dermatol Clin2000;18:711–25, x.
38.
KnowlesSRShapiroLEShearNH. Drug interactions of clinical significance for the dermatologist. Am J Clin Dermatol2003;4:623–39.
39.
Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry2006;51(8 Suppl 2):51S–5S.
40.
GormanJM. Treatment of generalized anxiety disorder. J Clin Psychiatry2002;63Suppl 8:17–23.
41.
BielskiRJBoseAChangCC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry2005;17:65–9.
42.
BallSGKuhnAWallD. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a doubleblind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry2005;66:94–9.
43.
AllgulanderCDahlAAAustinC. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry2004;161:1642–9.
44.
GelenbergAJLydiardRBRudolphRL. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA2000;283:3082–8.
NinanPTMuntasserS. Busiprone and gepirone. In: SchatzbergAFNemeroffCB, editors. Textbook of psychopharmacology. Washington (DC): American Psychiatric Publishing; 2004. p. 391–421.
47.
Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmacists Association; 2006.
48.
KoblenzerCS. Psychiatric syndromes of interest to dermatologists. Int J Dermatol1993;32:82–8.
49.
BlierPHabibRFlamentMF. Pharmacotherapies in the management of obsessive-compulsive disorder. Can J Psychiatry2006;51:417–30.
50.
MuraseJEWuJJKooJ. Morgellons disease: a rapport-enhancing term for delusions of parasitosis. J Am Acad Dermatol2006;55:913–4.
51.
LorenzoCRKooJ. Pimozide in dermatologic practice: a comprehensive review. Am J Clin Dermatol2004;5:339–49.
52.
DestaZKerbuschTSoukhovaN. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther1998;285:428–37.
53.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care2004;27:596–601.
54.
MeehanWJBadreshiaSMackleyCL. Successful treatment of delusions of parasitosis with olanzapine. Arch Dermatol2006;142:352–5.
55.
Yasui-FurukoriNHidestrandMSpinaE. Different enantioselective 9-hydroxylation of risperidone by two human CYP 2D6 and CYP3A4 enzymes. Drug Metab Dispos2001;29:1263–8.
56.
SpinaEScordoMGD'ArrigoC. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol2003;17:517–38.
57.
SpinaEAvenosoAFacciolaG. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit2000;22:481–5.
58.
KassahunKMattiuzENyhartEJr. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos1997;25:81–93.
